AVEO Pharmaceuticals (AVEO Pharmaceuticals) Days Payable : 99.49 (As of Sep. 2022)

View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Days Payable?

AVEO Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2022 was $4.32 Mil. AVEO Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2022 was $3.96 Mil. Hence, AVEO Pharmaceuticals's Days Payable for the three months ended in Sep. 2022 was 99.49.

The historical rank and industry rank for AVEO Pharmaceuticals's Days Payable or its related term are showing as below:

AVEO' s Days Payable Range Over the Past 10 Years
Min: 122.52 Med: 234.7 Max: 234.7
Current: 122.52

During the past 13 years, AVEO Pharmaceuticals's highest Days Payable was 234.70. The lowest was 122.52. And the median was 234.70.

AVEO's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 148.78 vs AVEO: 122.52

AVEO Pharmaceuticals's Days Payable declined from Sep. 2021 (211.57) to Sep. 2022 (99.49). It may suggest that AVEO Pharmaceuticals accelerated paying its suppliers.

AVEO Pharmaceuticals Days Payable Historical Data

The historical data trend for AVEO Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Days Payable Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Days Payable

Get a 7-Day Free Trial

234.70

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Payable	Get a 7-Day Free Trial															211.57	171.39	107.33	98.53	99.49

Competitive Comparison of AVEO Pharmaceuticals's Days Payable

For the Biotechnology subindustry, AVEO Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVEO Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Days Payable falls into.

AVEO Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

AVEO Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

	Days Payable (A: Dec. 2021 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2020 )	+	Accounts Payable (A: Dec. 2021 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2021 )	*	Days in Period
=	( (3.38	+	2.712)	/	2 )	/	4.737	*	365
=	3.046					/	4.737	*	365
=	234.70

AVEO Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2022 is calculated as:

	Days Payable (Q: Sep. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2022 )	+	Accounts Payable (Q: Sep. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
=	( (3.605	+	5.039)	/	2 )	/	3.964	*	365 / 4
=	4.322					/	3.964	*	365 / 4
=	99.49

AVEO Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Executives

Jebediah Ledell	officer: Chief Operating Officer	C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey	director, officer: President & CEO	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso	officer: Chief Commercial Officer	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell	10 percent owner
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera	officer: Chief Financial Officer	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring	director	AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202